DK1812015T3 - Methods for inhibition of nkt cells - Google Patents

Methods for inhibition of nkt cells

Info

Publication number
DK1812015T3
DK1812015T3 DK05851383.9T DK05851383T DK1812015T3 DK 1812015 T3 DK1812015 T3 DK 1812015T3 DK 05851383 T DK05851383 T DK 05851383T DK 1812015 T3 DK1812015 T3 DK 1812015T3
Authority
DK
Denmark
Prior art keywords
nkt cell
treatment
inhibition
methods
nkt cells
Prior art date
Application number
DK05851383.9T
Other languages
Danish (da)
English (en)
Inventor
Samuel Strober
Everett Hurteau Meyer
Dale T Umetsu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1812015T3 publication Critical patent/DK1812015T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK05851383.9T 2004-11-02 2005-11-02 Methods for inhibition of nkt cells DK1812015T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US70654805P 2005-08-08 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (1)

Publication Number Publication Date
DK1812015T3 true DK1812015T3 (en) 2013-01-02

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05851383.9T DK1812015T3 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Country Status (11)

Country Link
US (2) US7682614B2 (https=)
EP (1) EP1812015B1 (https=)
JP (1) JP4948418B2 (https=)
CN (1) CN101031307B (https=)
AT (1) ATE539757T1 (https=)
AU (1) AU2005310247A1 (https=)
CA (1) CA2584971C (https=)
DK (1) DK1812015T3 (https=)
ES (1) ES2378076T3 (https=)
PT (1) PT1812015E (https=)
WO (1) WO2006060117A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372668B1 (en) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
WO2012069572A1 (en) * 2010-11-25 2012-05-31 Imnate Sarl Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
CA2925878A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
CN107531787B (zh) 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
EP4480486A1 (en) * 2022-02-14 2024-12-25 Riken Nkt cell ligand-containing liposome composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
ES2201078T3 (es) 1993-06-21 2004-03-16 Brigham And Women's Hospital Metodos de aislar antigenos presentados por cd1, vacunas que comprenden antigenos presentados por cd1, y lineas celulares para usar en dichos metodos.
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE286735T1 (de) * 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
WO2000002923A1 (en) 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
AU2002213588A1 (en) 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
AU2001262697A1 (en) * 2000-06-06 2001-12-17 Kirin Beer Kabushiki Kaisha Method of amplifying natural killer t cells
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
WO2002016825A1 (fr) * 2000-08-18 2002-02-28 Mitsubishi Denki Kabushiki Kaisha Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
CN1487996B (zh) * 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
EP1372668B1 (en) * 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
HK1079882B (en) 2002-06-14 2011-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing colitis involving il-13 and nk-t cells
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
US20060104901A1 (en) 2002-08-27 2006-05-18 Angus Moodycliffe Preventing or treating epithelial tissue damage or hair loss
WO2004028475A2 (en) 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) * 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
ES2389080T3 (es) 2004-06-11 2012-10-23 Riken Fármaco que presenta un ligando de células reguladoras contenido en el liposoma

Also Published As

Publication number Publication date
WO2006060117A3 (en) 2007-03-01
CA2584971A1 (en) 2006-06-08
CA2584971C (en) 2013-08-06
US7682614B2 (en) 2010-03-23
US20100197613A1 (en) 2010-08-05
CN101031307A (zh) 2007-09-05
US20060116332A1 (en) 2006-06-01
EP1812015B1 (en) 2012-01-04
PT1812015E (pt) 2012-02-20
US8679499B2 (en) 2014-03-25
ES2378076T3 (es) 2012-04-04
WO2006060117A2 (en) 2006-06-08
EP1812015A4 (en) 2008-02-20
JP2008518974A (ja) 2008-06-05
JP4948418B2 (ja) 2012-06-06
AU2005310247A1 (en) 2006-06-08
ATE539757T1 (de) 2012-01-15
CN101031307B (zh) 2012-09-05
EP1812015A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
DK1812015T3 (en) Methods for inhibition of nkt cells
Ip et al. Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management
Cripps et al. MDSC in autoimmunity
Fujio et al. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity
Sun et al. The ATP-P2X7 signaling axis is dispensable for obesity-associated inflammasome activation in adipose tissue
WO2008137758A3 (en) Amino acid lipids and uses thereof
Jervis et al. New CD1d agonists: synthesis and biological activity of 6 ″-triazole-substituted α-galactosyl ceramides
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
WO2009086504A3 (en) Collagen formulations for improved skin care
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
Carosella The tolerogenic molecule HLA-G
AR064220A1 (es) Formulacion liofilizada mab abeta
MX2009002937A (es) Metodo y sistema para infusion controlada de substancias terapeuticas.
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
WO2009151708A3 (en) Peptide analogs of alpha-melanocyte stimulating hormone
KR101983566B1 (ko) 피부 외용제 조성물
Guiard et al. Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid govern T cell response
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
Chen et al. Hydrogen treatment protects mice against chronic pancreatitis by restoring regulatory T cells loss
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
Pareek et al. Melittin as a therapeutic agent for rheumatoid arthritis: mechanistic insights, advanced delivery systems, and future perspectives
Yin et al. Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting